An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia

Giuseppe Derosa; Angela D'Angelo; Arianna Vanelli; Pamela Maffioli

doi:10.2147/DMSO.S232791

An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia

Diabetes Metab Syndr Obes. 2020 Mar 3:13:653-661. doi: 10.2147/DMSO.S232791. eCollection 2020.

Authors

Giuseppe Derosa^{1

2

3}, Angela D'Angelo^{1

2}, Arianna Vanelli⁴, Pamela Maffioli^{1

3}

Affiliations

¹ Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
² Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy.
³ Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
⁴ Nutrilinea srl, Gallarate, Italy.

Abstract

Aim: To evaluate if a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate (Reglicem^®), can ameliorate glycemic status in patients with dysglycemia.

Methods: We enrolled 148 patients with impaired fasting plasma glucose or impaired glucose tolerance, not taking any hypoglycemic compounds. Patients were randomized to take nutraceutical or placebo for 3 months, in a randomized, double-blind, placebo-controlled design. Both nutraceutical and placebo were self-administered once a day, 1 tablet during the breakfast.

Results: A reduction of fasting and post-prandial plasma glucose was observed with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively). Furthermore, a decrease of glycated hemoglobin, and fasting plasma insulin was observed with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively). Then, there was a reduction of homeostasis model assessment index with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo). M value was higher (p < 0.05 vs baseline and p < 0.05 vs placebo) in the nutraceutical combination group at the end of the treatment. We observed a reduction of total cholesterol (TC) (p < 0.05 vs baseline) and triglycerides (Tg) (p < 0.05 vs baseline and p < 0.05 vs placebo) with the nutraceutical combination, respectively. Finally, high sensitivity C-reactive protein was reduced after 3 months with nutraceutical combination therapy (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively).

Conclusion: A nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate can be helpful in improving glyco-metabolic compensation, TC and Tg value, and in reducing inflammatory status in patients with dysglycemia.

Keywords: Banaba; Berberine; Chromium Picolinate; Curcuma; Inositol; dysglycemia.

Grants and funding

The research was supported by Nutrilinea srl, Gallarate, Italy. The funding source of this study did not have any role in conducting the study or in analysing data or in the writing of this paper.